Abstract
Fifty-one patients with advanced non-small cell lung carcinoma were treated with a combination of mitomycin C, vinblastine and cis-platin (MVP). Most cycles were given on an out-patient basis. Major side effects were leukopenia and peripheral neurotoxicity; one patient died of sepsis while leukopenic. In 44 evaluable patients the response rate was 50%, with one complete response. Overall median survival time was 280 days and median duration of responses was 232 days. A better performance status, disease limited to one hemithorax and no prior exposure to chemotherapy positively influenced the survival. MVP is an effective chemotherapy for non-small cell lung cancer and further experience with this combination is warranted.
Highlights
MVP is an effective chemotherapy for non-small cell lung cancer and further experience with this combination is warranted
Fifty-one patients with histologically or cytologically documented advanced NSCLC were entered in the study from September 1984 to June 1986 (Table I)
No patient was amenable to curative surgery or radiation, or had a performance status (ECOG) >3
Summary
Fifty-one patients with histologically or cytologically documented advanced NSCLC were entered in the study from September 1984 to June 1986 (Table I). No patient was amenable to curative surgery or radiation, or had a performance status (ECOG) >3. Measurable or evaluable disease was required of each subject. Bone lytic lesions were not considered evaluable if they were the only sites of disease. As well as radiation to lesions not used for response assessment. Patients were required to be off prior treatment for a minimum of 3 weeks and any toxicity associated with prior therapy resolved before entry into the study. Patients had to be no more than 70 years of age, have normal renal function (serum creatinine 60 ml min 1), normal marrow (leukocytes 4,000 mm platelets > 100,000mm 3), normal liver function (bilirubin
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call